Are Ozempic and Wegovy interchangeable since they're the same drug?

They share the same active ingredient (semaglutide), but they're approved with different titration schedules and different maximum maintenance doses — so they're not interchangeable at a matching dose. The same is true for Mounjaro and Zepbound (tirzepatide). Switching between them is a clinical decision your prescriber should plan deliberately, not a simple product swap.

If I switch from the diabetes version to the weight-management version, do I keep the same dose?

Not necessarily. Your prescriber needs to determine where your current dose actually corresponds to on the other version's titration schedule, which isn't always a direct one-to-one match given the different step structures. The weight-management versions generally have more titration steps and a higher eventual maintenance dose ceiling, so don't infer your new dose by matching pen strength numbers yourself.

Why would someone switch between the diabetes and weight-management versions of the same GLP-1?

The switch most often happens for insurance and coverage reasons, since diagnosis coding affects which brand a plan will cover. It can also happen when a person's primary treatment goal shifts over time — for example, moving from diabetes management toward a stronger weight-management focus — or because of availability.

What should I ask my prescriber before switching brands?

Three useful questions: where your current dose maps to on the new brand's titration schedule; whether you'll need to re-titrate from a lower dose or can transition more directly; and whether the switch affects your insurance coverage or requires a new prior authorization. That last one is often yes, so it's worth confirming before assuming the switch is administratively simple.

Switching between diabetes and weight-management dosing of the same drug

Ozempic and Wegovy — or Mounjaro and Zepbound — share an active ingredient, but they're not interchangeable at a matching dose. Here's why switching between them isn't a simple swap.

Updated Jul 18, 2026

Ozempic and Wegovy — like Mounjaro and Zepbound — contain the same active ingredient, so it's natural to assume moving between them is just a paperwork change. It isn't: the titration ladders differ, and understanding why makes the conversation with your prescriber much easier.

Same drug, different dosing structure

As covered in our guide on understanding insurance coverage, the diabetes and weight-management versions of the same GLP-1 medication — Ozempic/Wegovy (semaglutide) and Mounjaro/Zepbound (tirzepatide) — share the same active ingredient but are approved with different titration schedules and different maximum maintenance doses. The weight-management versions generally have more titration steps and a higher eventual maintenance dose ceiling than the diabetes versions of the same drug.

Why this matters if you're switching

If your prescriber is moving you from the diabetes-branded version to the weight-management-branded version (or vice versa) — whether for coverage reasons, a change in your primary treatment goal, or availability — this is not a same-dose product swap. Your prescriber needs to determine where in the titration schedule your current dose actually corresponds to, which isn't always a direct one-to-one match with where you were on the diabetes schedule, given the different step structures. This is a clinical decision that should be made deliberately with your prescriber, not inferred by matching pen strength numbers yourself.

dosingsemaglutidetirzepatideswitching

Was this helpful?

Common questions

Questions people often ask about this topic.

Are Ozempic and Wegovy interchangeable since they're the same drug?
They share the same active ingredient (semaglutide), but they're approved with different titration schedules and different maximum maintenance doses — so they're not interchangeable at a matching dose. The same is true for Mounjaro and Zepbound (tirzepatide). Switching between them is a clinical decision your prescriber should plan deliberately, not a simple product swap.
If I switch from the diabetes version to the weight-management version, do I keep the same dose?
Not necessarily. Your prescriber needs to determine where your current dose actually corresponds to on the other version's titration schedule, which isn't always a direct one-to-one match given the different step structures. The weight-management versions generally have more titration steps and a higher eventual maintenance dose ceiling, so don't infer your new dose by matching pen strength numbers yourself.
Why would someone switch between the diabetes and weight-management versions of the same GLP-1?
The switch most often happens for insurance and coverage reasons, since diagnosis coding affects which brand a plan will cover. It can also happen when a person's primary treatment goal shifts over time — for example, moving from diabetes management toward a stronger weight-management focus — or because of availability.
What should I ask my prescriber before switching brands?
Three useful questions: where your current dose maps to on the new brand's titration schedule; whether you'll need to re-titrate from a lower dose or can transition more directly; and whether the switch affects your insurance coverage or requires a new prior authorization. That last one is often yes, so it's worth confirming before assuming the switch is administratively simple.

Improve this page

Switching between diabetes and weight-management dosing of the same drug

Same drug, different dosing structure

Why this matters if you're switching

Common questions

Why this comes up

What to ask your prescriber

The bottom line

Related guides